Philippine FDA Requires Licenses for Vape Products with Medical Claims

Dec.22.2025
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.

Key Points

 

  • The Philippine FDA issued Advisory No. 2025-1487;
  • Vape products with medicinal claims must secure Licenses to Operate;
  • All manufacturers, importers, distributors and retailers are covered;
  • Products must be registered as pharmaceutical products;
  • Compliance is required to ensure safety and quality standards.

 


 

2Firsts, December 2025,22 – According to SunStar Philippines, the Philippine Food and Drug Administration (FDA) now requires all establishments selling Vaporized Nicotine and Non-Nicotine Products (VNNPs) and Novel Tobacco Products (NTPs) with medicinal or therapeutic claims to secure Licenses to Operate.

 

Based on Advisory No. 2025-1487, the FDA said that manufacturers, traders, importers, exporters, wholesalers and retailers offering such products must apply for licenses as pharmaceutical establishments under the Department of Health.

 

The FDA added that all VNNPs and NTPs with medicinal or therapeutic claims must be registered prior to manufacture, distribution and sale.

 

The agency said these products must be registered as pharmaceutical products through the Center for Drug Regulation and Research (CDRR).

 

The FDA urged all stakeholders to fully comply with the new requirements, stating that adherence to regulatory standards is necessary to ensure the safety, efficacy and quality of VNNPs and NTPs with medicinal or therapeutic claims in the market.

 

Image Source: SunStar Philippines

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai
South Korea to Classify Synthetic Nicotine E-Cigarettes as Tobacco from April 2026
South Korea to Classify Synthetic Nicotine E-Cigarettes as Tobacco from April 2026
South Korea will implement amendments to its Tobacco Business Act on April 24, 2026, officially classifying synthetic nicotine liquid e-cigarettes as tobacco. This marks the first revision of the legal definition of tobacco since 1988. Once in effect, synthetic nicotine e-cigarettes will be subject to existing tobacco regulations, including health warnings, advertising restrictions, smoke-free area enforcement, and youth protection measures.
Dec.29 by 2FIRSTS.ai
British Columbia Sues Juul Over Youth Nicotine Addiction
British Columbia Sues Juul Over Youth Nicotine Addiction
British Columbia has filed a civil lawsuit against Juul Labs, alleging the company fuelled youth nicotine addiction through highly addictive products and deceptive marketing practices. The claim was submitted to the B.C. Supreme Court under the newly enacted Vaping Product Damages and Health Care Costs Recovery Act.
Dec.15 by 2FIRSTS.ai
South Korean Court Strikes Down Health Levy on Vape Nicotine Liquids, Citing Disproportionate Penalties
South Korean Court Strikes Down Health Levy on Vape Nicotine Liquids, Citing Disproportionate Penalties
A Seoul court has annulled South Korea’s health-levy assessments imposed on multiple importers of nicotine liquids used for vaping. While the court agreed the nicotine could be treated as “tobacco” because it was found to be leaf-derived, it ruled the levy—stacked with other taxes and calculated on a blunt, volume-only basis—was so severe it effectively deprived businesses of the ability to operate, breaching constitutional proportionality and equality standards.
Jan.26 by 2FIRSTS.ai
Iowa Targets Smoking Products With Tax Plan: Cigarettes to National Average, 15% Tax on Vapes and Consumable Hemp
Iowa Targets Smoking Products With Tax Plan: Cigarettes to National Average, 15% Tax on Vapes and Consumable Hemp
Iowa Gov. Kim Reynolds is proposing higher taxes on cigarettes and new taxes on vaping and consumable hemp products, arguing tobacco use is a key driver of lung cancer. The proposal comes as University of Iowa researchers release preliminary findings suggesting Iowa’s late-stage lung cancer burden is higher—and improving more slowly—than in neighboring states.
Feb.06 by 2FIRSTS.ai